Revelation Biosciences (REVB) announced that the Nasdaq Hearings Panel issued a decision letter granting Revelation’s request to continue its listing on The Nasdaq Stock Market, subject to its stock trading at or above $1.00 for at least ten consecutive trading days by February 14, 2025. Additionally, the Nasdaq Hearings Panel confirmed that the company has regained compliance with the Equity Requirement of Listing Rule 5550(b)(1) for which the company was issued a notice of delisting for failure to comply with Equity Requirement of Listing Rule 5550(b)(1) on August 14, 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REVB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue